The VICTORIA-1 trial showed an unprecedented benefit for the gedatolisib triplet, with a hazard ratio of 0.24 in PIK3CA wild-type patients. The dramatic improvement suggests that PAM pathway activation is a dominant resistance mechanism even without a PIK3CA mutation, opening a new treatment avenue.

The VICTORIA-1 trial found that re-introducing palbociclib in a triplet with gedatolisib was effective, even in patients who had just progressed on palbociclib. This suggests that gedatolisib targets and overcomes the primary resistance mechanism to the CDK4/6 inhibitor, re-sensitizing the cancer to it.

Retrospective analysis of the BOLERO-2 trial revealed that the mTOR inhibitor everolimus benefits patients irrespective of their PI3K mutation status. This challenges the assumption that pathway-targeted therapies are only effective when a specific mutation is present, suggesting broader mechanisms of action.

For high-risk patients with a PIK3CA mutation who progress while on or shortly after adjuvant endocrine therapy, the triplet regimen of enovalisib, a CDK4/6 inhibitor (palbociclib), and fulvestrant is a preferred, aggressive first-line metastatic treatment.

The IV drug gedatolisib, which inhibits the entire PI3K/AKT/mTOR pathway, is highly effective even in patients *without* PIK3CA mutations. This suggests pathway activation is not solely mutation-driven and creates a new option for a biomarker-negative patient group.

The VICTORIA-1 trial found that gedatolisib, a pan-PI3K/mTOR inhibitor, significantly improves progression-free survival in patients with PIK3CA *wild-type* tumors after CDK4/6 inhibitor progression. This is a crucial finding for a patient group lacking clear targeted options and broadens the utility of targeting the PI3K pathway beyond just mutated tumors.

For patients with a PIK3CA mutation who relapse on or shortly after adjuvant endocrine therapy, the INAVO120 trial established a new standard of care. Adding inavolisib to palbociclib and fulvestrant significantly improved overall survival by seven months, providing a potent option for this particularly high-risk, endocrine-resistant population.

The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.

While initially approved for PIK3CA wild-type patients, Gedatolisib also doubled progression-free survival in patients with PIK3CA mutations compared to the standard of care. This mutation-agnostic benefit simplifies treatment decisions for clinicians, broadens the drug's applicability, and removes the need for mutation-specific testing to determine eligibility.